Opigolix is primarily researched for its potential therapeutic applications in the treatment of endometriosis and uterine fibroids. It functions as a gonadotropin-releasing hormone (GnRH) antagonist, which helps in reducing the production of estrogen and progesterone. This mechanism is particularly beneficial in managing symptoms associated with these conditions, such as pelvic pain and heavy menstrual bleeding. By targeting hormone levels, Opigolix aims to provide a non-surgical treatment option, improving the quality of life for patients suffering from these gynecological disorders. Clinical trials are ongoing to further evaluate its efficacy and safety in these applications.